Mosaic vaccines for serotype a foot-and-mouth disease virus
Patent
·
OSTI ID:1496592
Synthetic foot-and-mouth disease virus (FMDV) mosaic polypeptides, and nucleic acid molecules encoding the mosaic polypeptides, are described. The mosaic polypeptides have greater T-cell epitope coverage than naturally occurring FMDV polypeptides, and include common FMDV epitopes, but exclude rare FMDV epitopes. When included as part of an FMDV genome, the mosaic polypeptides permit virus replication and assembly into FMDV particles. The mosaic polypeptide and nucleic acid compositions can be used to elicit immune responses that provide protection against a broad range of serotype A FMDV strains.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC52-06NA25396
- Assignee:
- The United States of America, as represented by The Secretary of Agriculture (Washington, DC)
- Patent Number(s):
- 10,172,933
- Application Number:
- 15/785,875
- OSTI ID:
- 1496592
- Resource Relation:
- Patent File Date: 2017 Oct 17
- Country of Publication:
- United States
- Language:
- English
Foot and mouth disease virus with increased stability and its use as vaccine
|
patent | September 2015 |
Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in cattle
|
journal | July 2016 |
Similar Records
Transiently Transfected Mammalian Cell Cultures: An Adaptable and Effective Platform for Virus-like Particle-Based Vaccines against Foot-and-Mouth Disease Virus
Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine
Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine
Journal Article
·
Sat May 07 00:00:00 EDT 2022
· Viruses
·
OSTI ID:1496592
+7 more
Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine
Journal Article
·
Sat Oct 13 00:00:00 EDT 2018
· Vaccine
·
OSTI ID:1496592
+11 more
Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine
Journal Article
·
Thu Feb 01 00:00:00 EST 2018
· Vaccine
·
OSTI ID:1496592
+9 more